JP Morgan Upgrades ResMed to Overweight, Raises Price Target to $270
JP Morgan analyst David Low upgrades ResMed (NYSE:RMD) from Neutral to Overweight and raises the price target from $260 to $270.
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that encompassed the JPM Healthcare conference.
What 4 Analyst Ratings Have To Say About ResMed
Within the last quarter, ResMed (NYSE:RMD) has observed the following analyst ratings:
CLSA Upgrades ResMed to Buy
CLSA analyst Andrew Paine upgrades ResMed (NYSE:RMD) from Outperform to Buy.
Keybanc Upgrades ResMed to Overweight, Announces $302 Price Target
Keybanc analyst Matthew Mishan upgrades ResMed (NYSE:RMD) from Sector Weight to Overweight and announces $302 price target.
Macquarie Upgrades ResMed to Outperform
Macquarie analyst David Bailey upgrades ResMed (NYSE:RMD) from Neutral to Outperform.
CNBC’s Final Trades: Fiserv, ResMed, Monster Beverage And This Semiconductor Company
On CNBC’s “Halftime Report Final Trades,” Jenny Harrington of Gilman Hill Asset Management said Fiserv Inc (NASDAQ: FISV) belongs to its growth portfolio.
RBC Capital Maintains Underperform on ResMed, Lowers Price Target to $227
RBC Capital maintains ResMed (NYSE:RMD) with a Underperform and lowers the price target from $233 to $227.